证券代码：300981 证券简称：中红医疗 公告编号：2025-097 中红普林医疗用品股份有限公司 关于 2025 年前三季度计提减值准备的公告 （一）2025 年前三季度计提减值准备概况 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》和公司主要 会计政策、会计估计等相关制度要求，为了更加真实、准确反映公司及控股子公 司截至 2025 年 9 月 30 日的资产及经营状况，基于谨慎性原则，公司及控股子公 司对可能发生资产减值损失的应收款项、存货等计提减值准备，2025 年前三季 度计提金额合计为 2,761.08 万元。具体如下： 单位：万元 | 项目 | 年初至本报告期末增加金额 | | 年初至本报告期末转 | | --- | --- | --- | --- | | | 计提金额 | 其他变动 | 回/核销/转销 | | 应收账款坏账准备 | 269.35 | -5.35 | 3.25 | | 其他应收款坏账准备 | -18.21 | | 192.59 | | 存货跌价损失 | 2,509.94 | 0.08 | 2,832.77 | | 合计 | 2,761.08 | -5.27 | 3,02 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-094 中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十三 次会议于 2025 年 10 月 28 日以通讯方式召开，2025 年 10 月 23 日公司以电话和 电子邮件方式向全体董事发出会议通知。会议应参加表决的董事 9 人，实际参加 表决董事 9 人，会议由董事长桑树军先生主持，公司高管和相关人员列席了会议。 会议的召集、召开符合相关法律、法规和公司章程的规定。 二、会议审议情况 1. 审议通过《关于〈2025 年第三季度报告全文〉的议案》 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《2025 年第三季度报告》（公告编号：2025-096）。 2. 审议通过《关于 2025 年前三季度计提减值准备的议案》 《关于 2025 年前三季度计提减值准备的议案》经审计委员会全体成员同意 后，提交董事会审议。 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥626,124,015, a decrease of 9.24% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥12,953,080, representing a decline of 170.01% year-over-year[5]. - The basic earnings per share for Q3 2025 was -¥0.0303, down 169.98% from ¥0.0476 in the previous year[5]. - Total operating revenue for Q3 2025 was CNY 1,863,658,896.34, an increase from CNY 1,838,289,686.09 in the same period last year, representing a growth of approximately 1.4%[24]. - The net profit for Q3 2025 was a loss of CNY 9,563,733.87, compared to a profit of CNY 54,983,642.44 in the previous year, indicating a significant decline in profitability[25]. - The company reported a gross profit margin of approximately 10.0% for the quarter, down from the previous year's margin[24]. - Total comprehensive income for the period was -10,623,682.43 yuan, a significant decrease from 55,483,512.45 yuan in the previous period[26]. - Basic and diluted earnings per share were both -0.0169 yuan, compared to 0.1193 yuan in the previous period[26]. Assets and Liabilities - Total assets increased by 5.83% to ¥7,652,079,297.02 compared to the end of the previous year[5]. - The company's total assets increased to CNY 7,652,079,297.02 from CNY 7,230,360,796.53, marking a growth of approximately 5.8%[22]. - The company's total liabilities decreased by 1.93% compared to the end of the previous year[5]. - The total liabilities increased to CNY 2,143,741,020.00 from CNY 1,609,675,196.61, representing a rise of about 33.0%[22]. - Current liabilities rose to CNY 1,532,393,835.34 from CNY 1,236,429,413.12, an increase of about 25.0%[22]. - The company's equity attributable to shareholders decreased to CNY 5,368,713,903.59 from CNY 5,474,102,359.07, a decline of about 1.9%[22]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥90,666,375.21, a significant decrease of 790.08% year-over-year[13]. - Cash flow from operating activities showed a net outflow of -90,666,375.21 yuan, down from a net inflow of 13,138,484.56 yuan in the previous period[28]. - Cash inflow from investment activities was 4,877,338,484.37 yuan, an increase from 2,943,491,567.62 yuan in the previous period[28]. - Cash outflow from investment activities totaled 4,977,439,662.24 yuan, compared to 2,466,033,252.54 yuan in the previous period[28]. - Net cash flow from financing activities was 387,456,527.41 yuan, up from 145,056,064.44 yuan in the previous period[28]. - The ending balance of cash and cash equivalents was 782,330,697.99 yuan, down from 1,379,968,070.39 yuan in the previous period[28]. - The company reported a cash inflow of 1,755,371,866.76 yuan from sales of goods and services, an increase from 1,640,649,089.77 yuan in the previous period[27]. - The company’s total cash outflow for operating activities was 2,077,628,083.36 yuan, compared to 1,882,413,327.29 yuan in the previous period[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,418, with no preferred shareholders having restored voting rights[14]. - The largest shareholder, Zhonghong Pulin Group Co., Ltd., holds 45.01% of shares, totaling 193,050,000 shares[14]. - Xiamen Guomao Holdings Group Co., Ltd. owns 15.15% of shares, amounting to 64,993,500 shares[14]. - The total number of restricted shares held by the top shareholder, Sang Shujun, is now 35,830,080 after an increase of 3,257,280 shares[17]. - The company has a total of 1,436,202 shares in its repurchase account, representing 0.33% of the total share capital[15]. - There are no changes in the participation of the top 10 shareholders in margin trading or securities lending[16]. Borrowings and Expenses - The company reported a 115.16% increase in short-term borrowings, totaling ¥842,421,511.72, primarily due to increased financing[10]. - Short-term borrowings surged to CNY 842,421,511.72 from CNY 391,527,277.31, reflecting a significant increase of approximately 115.5%[22]. - The company incurred a total of 299,081,573.33 yuan in employee compensation, slightly up from 291,201,009.27 yuan in the previous period[28]. - Research and development expenses for the quarter were CNY 37,187,779.66, up from CNY 35,548,218.01, indicating an increase of approximately 4.6%[25]. Other Financial Metrics - The company’s investment income decreased by 34.31% to ¥8,761,768.44 compared to the same period last year[12]. - The trading financial assets amount to ¥1.84 billion, up from ¥1.73 billion at the beginning of the period[20]. - Accounts receivable increased to approximately ¥485.77 million from ¥427.48 million[20]. - Total operating costs increased to CNY 1,889,367,380.39 from CNY 1,796,999,850.39, reflecting a rise of about 5.1% year-over-year[24]. - The company experienced a 92.35% increase in prepayments, amounting to ¥92,556,323.80, attributed to higher advance payments for goods[10].

Core Insights - The article highlights the strategic partnership between Zhonghong Medical and Weimai Technology, focusing on the development of wireless temperature monitoring and intelligent temperature management systems, marking a significant step in the high-end medical market [1][2]. Group 1: Company Developments - Zhonghong Medical has invested in Weimai Technology, which specializes in digital vital sign management, enhancing its presence in the high-end medical sector [1]. - Weimai Technology's wireless temperature monitoring system received a Class II medical device registration in 2024, laying the foundation for Zhonghong Medical's expansion into high-end medical markets [1]. - The intelligent perioperative temperature management system developed by Weimai Technology has been implemented in renowned hospitals, receiving high recognition within the medical industry [2]. Group 2: Market Opportunities - The Japanese medical device market relies approximately 60% on imports, creating a significant opportunity for Weimai Technology's solutions, which are compatible with existing monitoring equipment and reduce procurement costs [3]. - The "one-time wear, full-process monitoring" model of Weimai Technology addresses the needs of elderly patients, alleviating the burden on healthcare staff [3]. Group 3: Strategic Collaboration - The partnership between Zhonghong Medical and Weimai Technology is characterized by deep cooperation in resource integration and complementary advantages, rather than mere capital injection [4]. - Zhonghong Medical has been authorized to distribute Weimai Technology's temperature monitoring and cardiopulmonary rehabilitation products, leveraging its established sales network to enhance market reach and revenue growth [4]. - This collaboration has opened new revenue streams for Zhonghong Medical, allowing it to enter the high-end intelligent medical device sector and build influence in the Asian high-end medical market [4]. Group 4: Future Prospects - The ongoing demand for medical intelligence and international market expansion presents further opportunities for collaboration between Zhonghong Medical and Weimai Technology [5]. - Weimai Technology plans to increase R&D investment to optimize product performance, while Zhonghong Medical will continue to support deeper cooperation with medical institutions across Asia [5]. - Both companies aim to contribute to global healthcare development by providing high-quality smart medical solutions, showcasing Chinese innovation on the world stage [5].

Core Viewpoint - Zhonghong Medical announced that its subsidiary, Zhonghong Medical Supplies (Hainan) Co., Ltd., has obtained the Medical Device Registration Certificate from the Hainan Provincial Drug Administration for a disposable nutrition pump tube medical device [1] Group 1 - The approval of the medical device registration certificate indicates a significant regulatory milestone for the company [1] - The registered product is a disposable nutrition pump tube, which is essential for medical applications [1]

Core Viewpoint - 中红医疗 is primarily engaged in the production and sales of medical and industrial disposable protective gloves, with a significant focus on overseas markets and ODM direct sales model [2][9]. Group 1: Company Overview - 中红医疗 is located in Tangshan, Hebei Province, and was established on December 22, 2010, with its listing date on April 27, 2021 [9]. - The company's main business revenue composition includes health protection products (89.48%), safety infusion products (6.22%), and innovative incubation products (4.30%) [9]. - As of June 30, 2025, 中红医疗 had a total market capitalization of 56.27 billion yuan [1]. Group 2: Financial Performance - For the first half of 2025, 中红医疗 achieved operating revenue of 1.238 billion yuan, representing a year-on-year growth of 7.76%, while the net profit attributable to the parent company was 5.7429 million yuan, a decrease of 82.35% year-on-year [10]. - The company reported that 81.56% of its revenue comes from overseas, benefiting from the depreciation of the RMB [4]. Group 3: Product and Innovation - 中红医疗 showcased its products at the 12th Beijing Pet Expo, highlighting the UniFusion SP50 Vet and UniFusion VP50 Vet veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture [2]. - The company emphasizes innovation and digital technology integration in product development, aiming to provide high-quality, innovative medical consumables and equipment [3]. Group 4: Market Position and Shareholder Information - 中红医疗 is classified as a state-owned enterprise, with the ultimate controller being the State-owned Assets Supervision and Administration Commission of the Xiamen Municipal People's Government [5]. - As of June 30, 2025, the number of shareholders was 20,200, an increase of 0.40% from the previous period, with an average of 19,502 circulating shares per person, up by 9.52% [10].

Core Viewpoint - Zhonghong Medical (300981.SZ) announced that its subsidiary, Zhonghong Medical Supplies (Hainan) Co., Ltd., has recently obtained the Medical Device Registration Certificate from the Hainan Provincial Drug Administration for its disposable nutrition pump tube medical device, which will enhance the company's product offerings in the nutrition pump consumables sector and strengthen its competitive edge [1] Group 1 - The acquisition of the Medical Device Registration Certificate is a significant milestone for Zhonghong Medical, as it allows the company to expand its product categories in the nutrition pump consumables field [1] - This development is expected to create brand and technological advantages for the company, further enhancing its overall competitiveness [1]

Core Viewpoint - Zhonghong Medical (300981.SZ) announced that its subsidiary, Hainan Zhonghong, has obtained the Medical Device Registration Certificate from the Hainan Provincial Drug Administration for a disposable nutrition pump tube, valid until October 15, 2030. This product is designed for delivering nutritional fluids into the gastrointestinal tract. The acquisition of this registration certificate is expected to enhance the company's product offerings in the nutrition pump consumables sector, establishing brand and technological advantages, although actual sales performance and its impact on future company earnings remain uncertain [1]. Summary by Category - **Product Development** - The company has received approval for a new medical device, a disposable nutrition pump tube, which is intended for gastrointestinal nutrition delivery [1]. - The registration certificate is valid until October 15, 2030, indicating a long-term opportunity for the company in this product line [1]. - **Market Positioning** - The approval is expected to enrich the company's product categories within the nutrition pump consumables market, potentially strengthening its brand and technological edge [1]. - **Financial Impact** - There is uncertainty regarding the actual sales performance of the new product and its future impact on the company's earnings [1].

Core Viewpoint - The company has obtained a medical device registration certificate for a disposable nutrition pump tube, enhancing its product offerings in the nutrition pump consumables sector [1] Summary by Categories Product Registration - The subsidiary Zhonghong Medical Supplies (Hainan) Co., Ltd. has received the "People's Republic of China Medical Device Registration Certificate" from the Hainan Provincial Drug Administration [1] - The registered product is classified as a Class II medical device, with a validity period from October 14, 2025, to October 13, 2030 [1] Market Impact - The acquisition of this medical device registration certificate will enrich the company's product categories in the nutrition pump consumables field [1] - This development is expected to create brand and technological advantages, further enhancing the overall competitiveness of the company and its subsidiaries [1]

上述产品实际销售情况取决于未来市场的推广效果，产品销售及利润贡献具 有不确定性，目前尚无法预测上述产品对公司未来业绩的影响，敬请投资者谨慎 决策注意防范投资风险。 一、基本信息 注册人名称 产品名称 注册证编号 注册分类 注册证有效期 适用范围 中红医疗用 品（海南） 有限公司 一次性使用 营养泵管 琼械注准 20252140097 Ⅱ类 2025 年 10 月 14 日 至 2030 年 10 月 13 日 产品适用于向胃肠内输 送营养液。 一次性使用 营养泵管 琼械注准 20252140098 Ⅱ类 2025 年 10 月 16 日 至 2030 年 10 月 15 日 产品适用于向胃肠内输 送营养液。 证券代码：300981 证券简称：中红医疗 公告编号：2025-093 中红普林医疗用品股份有限公司 关于子公司中红医疗用品（海南）有限公司 获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司中红医疗用品 （海南）有限公司（以下简称"海南中红"）于近期取得了海南省药品监督管理 局 ...